FLGT Jan 2024 145.000 call
| Previous close | 18.95 |
| Open | N/A |
| Bid | 7.10 |
| Ask | 10.80 |
| Strike | 145.00 |
| Expiry date | 2024-01-19 |
| Day's range | 18.95 - 18.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
ZacksFulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireFulgent Reports Second Quarter 2023 Financial Results
EL MONTE, Calif., August 04, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023.
GlobeNewswireExagen Inc. Appoints Paul Kim to Board of Directors
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (Nasdaq: FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increas
